GSK-626616

GSK-626616 is a potent, orally bioavailable small molecule inhibitor of dual-specificity tyrosine-regulated kinase 3 (DYRK3), with an IC50 of 0.7 nM. It also inhibits other DYRK family members such as DYRK1A and DYRK2 with similar potency, showing approximately 20-fold selectivity over casein kinase 2 and negligible activity against a broad panel of other kinases. Preclinical studies indicate that GSK‑626616 enhances erythroid colony formation in response to erythropoietin and increases hemoglobin levels in anemic mice, suggesting its potential as a therapy for anemia. The compound was initially developed by GSK for research purposes[1][2][3][4][7].

Other names

(5Z)-2-[(2,6-Dichlorophenyl)amino]-5-(6-quinoxalinylmethylene)-4(5H)-thiazoloneCHEMBL5081787CHEMBL-5081787CHEMBL 5081787OKY0RM282VOKY-0RM282VOKY 0RM282V1025821-33-3